Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Quadrivalent Influenza Vaccine Gains FDA Approval

XTALKS VITALS NEWS

Vaccine

According to a press release issued by the company, Flublok Quadrivalent is the only influenza vaccine approved by the FDA which contains a high antigen content.

Tweetables from this article:

Tweet: #Clinicaltrial: adults given the Flublok Quadrivalent #vaccine had a 40 percent lesser chance of contracting #influenza http://ctt.ec/9dkcZ+ #Clinicaltrial: adults given the Flublok Quadrivalent #vaccine had a 40 percent lesser chance of contracting #influenza.

Share this!

October 13, 2016 | by Sarah Hand, M.Sc.

Protein Sciences Corporation’s quadrivalent Flublok influenza vaccine has been approved by the US Food and Drug Administration (FDA). This latest version of the influenza vaccine protects against three of the same strains found in the previous trivalent Flublok, in addition to a fourth B strain of the virus.

According to a press release issued by the company, Flublok Quadrivalent is the only influenza vaccine approved by the FDA which contains a high antigen content. The vaccine is well-suited to the elderly and those with a compromised immune system as it contains three times more of the active ingredient, compared to other approved quadrivalent vaccines.



To test the efficacy of Flublok Quadrivalent in people over the age of 50, Protein Sciences conducted a 9,000 participant clinical trial. They found that adults given the Flublok Quadrivalent had a 40 percent lesser chance of contracting influenza, compared to those that were administered the leading quadrivalent vaccine.

“The U.S. has been trending toward the use of quadrivalent flu vaccines in recent years,” said Manon Cox, President and CEO of Protein Sciences Corporation. “We are pleased to bring Flublok Quadrivalent to market to give consumers additional options, especially seniors who have no other high antigen content quadrivalent vaccine available to them. We are looking forward to launching the vaccine next year and, in the meantime, continuing to make trivalent Flublok available this year.”

Flubok Quadrivalent has been approved by the FDA for use in patients 18 and older and will be available in early 2017. As a protein-based vaccine, it contains no infectious influenza virus, antibiotics, egg products or preservatives. Approved in 2013, the trivalent version of the vaccine is available in pharmacies throughout the US.


Keywords: Influenza, Vaccine, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.